RxDoctor Payments Data

Yuhoe Dice, MD

Internal Medicine · San Antonio, TXNPI 1316919020

Payments from drug & device makers

$9,234in general payments, 2019–2025

Across 568 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Amgen$779
  • AstraZeneca$516
  • Daiichi Sankyo Inc.$433
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,15299%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,234 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$110,660
Medicare patients
291
Services billed
1,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide179$234,643
EliquisApixaban52$69,846
JardianceEmpagliflozin41$62,305
XareltoRivaroxaban39$55,800
ProliaDenosumab16$27,737
FarxigaDapagliflozin Propanediol20$22,590
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$15,535
Soliqua 100-33Insulin Glargine/Lixisenatide13$14,468
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$14,192
MyrbetriqMirabegron16$12,892
Tresiba Flextouch U-200Insulin Degludec18$10,554
Breo ElliptaFluticasone/Vilanterol11$8,904
Levothyroxine Sodium530$6,038
SynthroidLevothyroxine Sodium73$4,439
ShingrixVaricella-Zoster Ge/As01b/Pf19$4,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,608$234,643179 claims
PfizerEliquis, Premarin, Abrysvo$399$77,77976 claims
Boehringer IngelheimJardiance$145$62,30541 claims
Johnson & JohnsonXarelto$88$55,80039 claims
AstraZenecaFarxiga, Breztri Aerosphere$516$36,78137 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$296$28,69855 claims
AmgenProlia$779$27,73716 claims
Astellas Pharma US IncMyrbetriq$197$12,89216 claims
AbbVieSynthroid$1,293$4,43973 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →